Abstract OBJECTIVE: To examine serum concentration of interleukin-18 (IL-18) and IL-18 mRNA expression in peripheral blood mononuclear cells (PBMCs) in children with primary nephrotic syndrome (PNS) and explore the possible role of IL-18 in steroid-resistant nephrotic syndrome (SRNS). METHODS: Sixty-six children with newly diagnosed PNS, including 39 cases of steroid sensitive nephrotic syndrome (SSNS) and 27 cases of SRNS, were enrolled. Forty healthy children were used as a normal control group. Blood samples were collected before and 8 weeks after glucocorticoid treatment. Serum concentration of IL-18 was measured using ELISA. IL-18 mRNA expression in PBMCs was detected by the RT-PCR method. The amount of 24-hr urine protein was measured by the biuret method. Serum contents of total cholesterol (T-Ch), triglyceride (TG), low density lipoprotein (LDL), total protein (TP), and albumin (Alb) were measured by the automatic biochemistry analyzer. RESULTS: Serum concentration of IL-18 and IL-18 mRNA expression in PBMCs in the SSNS and the SRNS groups were significantly higher than those in the normal control group before treatment (P<0.05). The SRNS group had increased serum protein concentration of IL-18 and IL-18 mRNA expression in PBMCs compared with the SSNS group before treatment (P<0.05). Serum LDL content in the SRNS group was also significantly higher than that in the SSNS group before treatment (P<0.05). After treatment, serum concentration of IL-18 and IL-18 mRNA expression in PBMCs in the SRNS group were significantly higher than those in the SSNS and the normal control groups (P<0.05). Serum concentration of IL-18 and IL-18 mRNA expression in PBMCs in the SSNS group were significantly reduced after treatment, but the alterations of IL-18 were not observed in the SRNS group after treatment. CONCLUSIONS: SRNS was associated with increased serum IL-18 concentration and IL-18 mRNA expression in PBMCs. Over-production of IL-18 may play a role in the development of SRNS.［Chin J Contemp Pediatr, 2009, 11 (5):337-340］
［1］Schachter AD. The pediatric nephrotic syndrome spectrum: clinical homogeneity and molecular heterogeneity［J］. Pediatr transplantation, 2004, 8(4):344-348.
［2］Tain YL, Chen TY, Yang KD. Implications of serum TNF-beta and IL-13 in the treatment response of childhood nephrotic syndrome［J］. Cytokine, 2003, 21(3):155-159.
［5］Vanholder R, van Laecke S, Glorieux G. What is new in uremic toxicity［J］. Pediatr Nephrol, 2008, 23(8):1211-1221.
［6］Kili＇s-Pstrusińska K, Medyńska A, Zwolińska D, Wawro A. Interleukin-18 in urine and serum of children with idiopathic nephrotic syndrome［J］. Kidney Blood Press Res, 2008, 31(2):122-126.
［9］Sugiyama M, Kinoshita K, Kishimoto K, Shimazu H, Nozaki Y, Ikoma S, et al. Deletion of IL-18 receptor ameliorates renal injury in bovine serum albumin-induced glomerulonephritis［J］. Clin Immunol, 2008, 128(1):103-108.
［10］Bakr A, Shokeir M, El-Chenawi F, El-Husseni F, Abdel-Rahman A, El-Ashry R.Tumor necrosis factor-alpha production from mononuclear cells in nephrotic syndrome［J］.Pediatr Nephrol, 2003, 18(6):516-520.
［11］Aviles DH, Matti Vehaskari V, Manning J, Ochoa AC, Zea AH.Decreased expression of T-cell NF-kappa p65 subunit in steroid-resistant nephrotic syndrome［J］. Kidney Int, 2004, 66(1):60-67.
［12］Kitching AR, Tipping PG, Kurimoto M, Holdsworth SR.IL-18 has IL-12-independent effects in delayed type hypersensitivity: studies in cellmediated crescentic glomerulonephritis［J］.J Immunol, 2000, 165(8):4649-4657.
［13］Bagga A, Mantan M. Nephrotic syndrome in children［J］. Indian J Med Res, 2005, 122（1）:13-28.
［14］Pawlak K, Mysliwiec M, Pawlak D. Oxidative stress, phosphate and creatinine levels are independently associated with vascular endothelial growth factor levels in patients with chronic renal failure［J］. Cytokine, 2008, 43(1):98-101.
［15］Miao L, Sun J, Yuan H, Jia Y, Xu Z.Combined therapy of low-dose tacrolimus and prednisone in nephrotic syndrome with slight mesangial proliferation［J］.Nephrology, 2006, 11(5):449-454.
［16］Kobayashi S. Applications of LDL-apheresis in nephrology［J］. Clin Exp Nephrol, 2008, 12(1):9-15.
［17］Mitsuoka H, Kume N, Hayashida K, Inui-Hayashiada A, Aramaki Y, Toyohara M, et al. Interleukin 18 stimulates release of soluble lectin-like oxidized LDL receptor-1 (sLOX-1) ［J］. Atherosclerosis, 2009, 202(1):176-182.
